Clinical trials
Hypertension trials in Taiwan with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
| 2013 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Unknown status | 6 |
| Recruiting | 5 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chung Shan Medical University | 3 |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | 3 |
| National Taiwan University Hospital | 3 |
| National Health Research Institutes, Taiwan | 2 |
| National Taipei University of Nursing and Health Sciences | 2 |
| Taipei Veterans General Hospital, Taiwan | 2 |
| Chang Gung Memorial Hospital | 1 |
| Chang Gung University of Science and Technology | 1 |
| Chien-Wen Hou | 1 |
| Chimei Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension | 27 |
| Diabetes Mellitus | 5 |
| Renal Insufficiency, Chronic | 4 |
| Dyslipidemias | 3 |
| Hyperglycemia | 3 |
| Hyperlipidemias | 3 |
| Diabetes Mellitus, Type 2 | 2 |
| Metabolic Syndrome | 2 |
| Alert Fatigue, Health Personnel | 1 |
| Alphavirus Infections | 1 |
Trials
Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.